Can Preventive Therapy Alter the Initial Presentation of Coronary Heart Disease?
Authors: Sidney C. Smith
Journal: Annals of Internal Medicine (2006)

Editorials21 February 2006Can Preventive Therapy Alter the Initial Presentation of Coronary Heart Disease?Sidney C. Smith Jr, MDSidney C. Smith Jr, MDFrom The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7075.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-4-200602210-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail During the past 2 decades, a large body of evidence has accumulated about the effects of medical therapies given to reduce the risk for events associated with coronary heart disease (CHD). These studies and trials have usually focused on hard end points, such as total mortality rate, fatal and nonfatal myocardial infarction, and sudden death. Together, these interventions reduce the risk for a CHD event, especially when used in patients with known CHD (secondary prevention) and in high-risk patients with no history of CHD (primary prevention). In contrast, we know little about how these primary preventive therapies affect the way ...References1. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, et al. Statin and β-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med. 2006;144:229-38. LinkGoogle Scholar2. American Heart Association. Heart Disease and Stroke Statistics—2006 Update. Dallas, TX: American Heart Association; 2006. Google Scholar3. Hsia J, Aragaki A, Bloch M, LaCroix AZ, Wallace R, et al. Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observational Study. Am J Cardiol. 2004;93:673-8. [PMID: 15019867] CrossrefMedlineGoogle Scholar4. Dunder K, Lind L, Lagerqvist B, Zethelius B, Vessby B, Lithell H. Cardiovascular risk factors for stable angina pectoris versus unheralded myocardial infarction. Am Heart J. 2004;147:502-8. [PMID: 14999201] CrossrefMedlineGoogle Scholar5. Spencer FA, Santopinto JJ, Gore JM, Goldberg RJ, Fox KA, Moscucci M, et al. Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2002;90:1056-61. [PMID: 12423703] CrossrefMedlineGoogle Scholar6. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized, controlled trials. JAMA. 2006;295:306-13. [PMID: 16418466] CrossrefMedlineGoogle Scholar7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7. [PMID: 7566020] CrossrefMedlineGoogle Scholar8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. [PMID: 9613910] CrossrefMedlineGoogle Scholar9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. [PMID: 16214597] CrossrefMedlineGoogle Scholar10. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence [Editorial]. Circulation. 2005;111:2280-1. [PMID: 15883224] CrossrefMedlineGoogle Scholar11. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:III39-43. [PMID: 15198965] CrossrefMedlineGoogle Scholar12. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103:1721-6. [PMID: 11282901] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Sidney C. SmithJr, MDAffiliations: From The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7075.Disclosures: Consultancies: Pfizer Inc.; Honoraria: Merck, Bristol-Myers Squibb; Other: Data Safety Monitoring Board, AstraZeneca Research Clinical Trial.Corresponding Author: Sidney C. Smith Jr., MD, Center for Cardiovascular Science and Medicine, The University of North Carolina at Chapel Hill, CB #7075, 6th Floor, Burnett-Womack Building, 99 Manning Drive, Chapel Hill, NC 27599-7075. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoStatin and β-Blocker Therapy and the Initial Presentation of Coronary Heart Disease Alan S. Go , Carlos Iribarren , Malini Chandra , Phenius V. Lathon , Stephen P. Fortmann , Thomas Quertermous , Mark A. Hlatky , and Metrics Cited byPreventive Cardiology 21 February 2006Volume 144, Issue 4Page: 296-297KeywordsAnginaCholesterolCoronary heart diseaseMyocardial infarctionStatins ePublished: 21 February 2006 Issue Published: 21 February 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...